NCT03251989View on ClinicalTrials.gov

Rare CNS Tumors Outcomes &Risk

CompletedOBSERVATIONAL
Enrollment

326

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

May 6, 2025

Study Completion Date

May 6, 2025

Conditions
High Grade MeningiomaEpendymomaMedulloblastomaPNETPrimary CNS Sarcoma
Trial Locations (1)

20892

National Cancer Institute (NCI)/ Neuro-Oncology Branch, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03251989 - Rare CNS Tumors Outcomes &Risk | Biotech Hunter | Biotech Hunter